|1.||Riddle, David R: 2 articles (07/2011 - 01/2010)|
|2.||Conner, Kelly R: 2 articles (07/2011 - 01/2010)|
|3.||Forbes, M Elizabeth: 2 articles (07/2011 - 01/2010)|
|4.||Gerdes, A Martin: 2 articles (08/2006 - 02/2002)|
|5.||Rosa, E: 1 article (02/2012)|
|6.||Hehre, D: 1 article (02/2012)|
|7.||Ramos, S G: 1 article (02/2012)|
|8.||Martins, A R: 1 article (02/2012)|
|9.||Suguihara, C: 1 article (02/2012)|
|10.||Camelo Jr, J S: 1 article (02/2012)|
|1.||Hypertension (High Blood Pressure)
12/01/1997 - "Alteration in arterial structure due to L-158,809 treatment was found only when measured at a transmural pressure of 100 mm Hg. In conclusion, L-158,809 was effective in preventing hypertension during the treatment period, in reducing hypertension severity during the withdrawal period, and in persistently decreasing the reactivity of the arteries."
02/01/1997 - "Untreated PHN rats developed hypertension, while rats with PHN given lisinopril or L-158,809 all had systolic blood pressure values even lower than those of normal rats. "
08/01/1998 - "Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension."
01/01/1997 - "The purpose of this study was to asses the effects of enalaprilat and L-158,809, an angiotensin II type-1 receptor antagonist, on LV diastolic function in 16 normal control dogs and 20 LVH dogs with perinephritic hypertension. "
02/01/1998 - "We studied effects of enalaprilat and L-158,809, an angiotensin II type-1 receptor antagonist, on left ventricular (LV) diastolic relaxation in 11 normal control dogs and 16 LV hypertrophied (LVH) dogs with perinephritic hypertension. "
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
02/01/1997 - "Although L-158,809 had no effect on baseline renal sympathetic nerve activity in normal rabbits, analysis of the data in the heart failure rabbits indicated that baseline renal sympathetic nerve activity was reduced from 33 +/- 5% to 17 +/- 4% after L-158,809 administration after adjustment for changes in arterial pressure. "
07/01/1996 - "beta 1-Blockade had no effect on any baroreflex parameter after L-158,809 in rabbits with heart failure. "
07/01/1996 - "However, in rabbits with heart failure, L-158,809 enhanced baroreflex sensitivity (2.7 +/- 0.5 vs. 4.7 +/- 0.8 beats.min-1.mmHg-1; P < 0.05), primarily by increasing the minimum HR evoked during baroreceptor activation. "
02/01/2002 - "A recent study showed reverse remodeling of left ventricular myocyte shape when the type 1 angiotensin II (AT1)-receptor antagonist L-158,809 was administered to spontaneously hypertensive heart failure (SHHF) rats 4 months before the onset of failure. "
08/01/2006 - "Angiotensin II type 1 receptor blocker L-158,809 (ARB) induces reverse left ventricular (LV) remodeling in spontaneously hypertensive heart failure (SHHF) rats. "
07/01/2010 - "However, L-158809 did not have similar beneficial effects on acute pancreatitis in rats while losartan decreased pancreatic parenchymal necrosis and neutrophil infiltration. "
07/01/2010 - "This study not only demonstrated the differential effects of captopril, losartan and L-158809 in acute pancreatitis but also showed that there is still much to investigate about pancreatic renin-angiotensin system. "
07/01/2010 - "The aim of this study was to evaluate the therapeutic potential of angiotensin-converting-enzyme inhibition by captopril and angiotensin II type 1 receptor inhibition by L-158809 and losartan experimentally in acute pancreatitis. "
|3.||Type 1 Angiotensin Receptor
|8.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|10.||Angiotensin Receptors (Angiotensin II Receptor)